

## EBI Report

type of report	Current report
number	12/2013
company	PHARMENA

### Obtaining a patent in Europe

With reference to report no. 80/2012 of 28<sup>th</sup> November 2012 (Information on intent to grant patent in Europe), the Management Board of PHARMENA S.A. declares that on 22<sup>nd</sup> March 2013, CORTRIA CORPORATION, a subsidiary company of PHARMENA S.A. received notification that it was granted a patent no. EP 2026651 by European Patent Office.

The above patent will provide protection for the oral use of 1-methylnicotinamide (1-MNA) in combination with non-steroidal anti-inflammatory drugs in treatment of pain and inflammations of various origins on leading European markets, including: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Holland, Hungary, Ireland, Island, Italy, Liechtenstein, Lithuania, Luxemburg, Monaco, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom.

NSAIDs are a vast and very popular group of medicinal products with anti-inflammatory, analgesic, and antipyretic effect. The group includes such popular medicinal products as: aspirin, diclofenac, ibuprofen, and naproxen. They are used for symptomatic treatment of inflammation, fever or pain of various origins. They are available over the counter which adds to their popularity among patients. However, a prolonged use of NSAIDs may lead to gastrointestinal complications. Patients using medicinal products of this group observe abdominal pain, discomfort, heartburn, nausea, and increased risk of stomach ulcers. Concomitant use of NSAIDs and 1-MNA may prevent such complications.

This patent is of great importance to the process of commercialisation of the 1-MNA project, due to the fact that global market of pain-relief treatments will amount to 38 billion USD in 2012 (according to BCC Research). The segment of NSAIDs constitutes 28% of that market.

The information is made public due to the fact that it may influence the asset valuation of PHARMENA S.A. in the form of patent application described in the report, which Cortria Corporation (a subsidiary company of PHARMENA S.A.) possesses rights to, as well as because of participation in potential revenue resulting from commercialisation of the aforementioned patent application.

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

#### Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board